lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy

lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy

Glioblastoma (GBM) is the most common and lethal type of primary malignant central nervous system (CNS) tumor with an extremely poor prognosis, and the mesenchymal subtype of GBM has the worst prognosis. Here, we found that lncRNA PRADX was overexpressed in the mesenchymal GBM and was transcriptiona...

Full description

Bibliographic Details
Main Authors: Can Xu, Jixing Zhao, Jia Song, Menglin Xiao, Xiaoteng Cui, Lei Xin, Jianglong Xu, Yuhao Zhang, Kaikai Yi, Biao Hong, Fei Tong, Shaohui Tian, Yanli Tan, Chunsheng Kang, Chuan Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
mesenchymal GBM
lncRNA
RUNX1-CBFβ complex
STAT3 pathway
energy metabolism
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.888922/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.888922/full

Similar Items